SCHEMBL5856835

SCHEMBL5856835

CCOC(=O)c1ccc2c(c1)NC(=O)C2=C(Nc1ccc(N(C)C(=O)CCN(C)C)cc1)c1ccc2c(c1)OCCO2

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.47
LMNA P02545 3/20 0.47
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47
GAA P10253 1/20 0.45
RAB9A P51151 3/20 0.43
TSHR P16473 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
RXFP1 Q9HBX9 2/20 0.40
NPC1 O15118 2/20 0.39
HSP90AA1 P07900 1/20 0.39
KDM4E B2RXH2 3/20 0.39
POLB P06746 2/20 0.38
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5856820 1.00 MAPT (0.47) MAPTLMNAMEN1USP2MAPK1
SCHEMBL3935399 0.95 RAB9A (0.49) MAPTLMNAMEN1USP2MAPK1
SCHEMBL3935387 0.95 RAB9A (0.49) MAPTLMNAMEN1USP2MAPK1
SCHEMBL3933669 0.93 MAPT (0.47) MAPTLMNAMEN1USP2MAPK1
SCHEMBL3933665 0.93 MAPT (0.47) MAPTLMNAMEN1USP2MAPK1
SCHEMBL3933010 0.90 MAPT (0.45) MAPTLMNAMEN1USP2MAPK1
SCHEMBL3933011 0.90 MAPT (0.45) MAPTLMNAMEN1USP2MAPK1
SCHEMBL3943005 0.89 RAB9A (0.49) MAPTLMNAMEN1USP2MAPK1
SCHEMBL3945038 0.89 MAPT (0.47) MAPTLMNAMEN1USP2MAPK1
SCHEMBL3945034 0.89 MAPT (0.47) MAPTLMNAMEN1USP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
EP-1551830-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-07-13 EP disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed
WO-2004026829-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 MAPT 1798/4885LMNA 1567/4885MEN1 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.